热门资讯> 正文
Virios Therapeutics GAAP每股收益为-2.05美元
2024-11-07 22:55
- Virios Therapeutics press release (NASDAQ:DWTX): Q3 GAAP EPS of -$2.05.
- The company estimates that its current cash of $2M at Sept. 30 along with the $16.5M in loan proceeds received on Oct. 7 is not sufficient to fund operating expenses and capital requirements for at least the next 12 months.
- It will need to secure the additional $3M of loan proceeds available under the terms of the loan agreement in February 2025 to continue to fund operations through 2025.
- Shares -2.92%
More on Virios Therapeutics
- Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics
- Seeking Alpha’s Quant Rating on Virios Therapeutics
- Historical earnings data for Virios Therapeutics
- Financial information for Virios Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
